FTSE MIB
26.558,83 +659,26 (+2,55%) Dow Jones
32.244,58 +382,60 (+1,20%) Nasdaq
11.675,54 +45,02 (+0,39%) Nikkei 225
26.945,67 -388,12 (-1,42%) Petrolio
68,10 +0,46 (+0,68%) Bitcoin EUR
25.969,91 -272,75 (-1,04%)
Bristol-Myers Squibb Company (0R1F.L)
| Chiusura precedente | 72,50 |
| Aperto | 73,28 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 72,71 - 72,83 |
| Intervallo di 52 settimane | 72,71 - 72,83 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 1,2B |
| Beta (5 anni mensile) | 0,45 |
| Rapporto PE (ttm) | 0,26 |
| EPS (ttm) | 2,82 |
| Prossima data utili | 27 apr 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
- GlobeNewswire
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from Brist
- GlobeNewswire
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties - LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol M
